NCT04158050

Comparison of Biologicals in Treatment of Severe Asthma

Comparison of Biologicals in Treatment of Severe Asthma - Real Life Experiences

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 64 (actual)
• Sponsor: Helsinki University Central Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

This is a retrospective clinical study on adult patients (18 years or more) with biological therapy for severe asthma at the Helsinki University Central Hospital (HUCH). This is a real-life study with a broader patient population than in a randomized controlled trial. Omalizumab has been used for treatment of asthma in HUCH since January 2009, anti-IL5 therapies starting with mepolizumab since April 2016.

Detailed description

The investigators collect and analyse results of anti-IL5/IL5R and anti-IgE therapies in asthma until October 2019.The investigators compare number of exacerbations, number of glucocorticoid courses, dose of per oral glucocorticoid, number of antibiotic courses, need of emergency care and hospitalizations because of asthma before use of biologicals and at the latest visits of the participants when using biologicals.

Conditions

• Asthma

Interventions

Type	Name	Description
DRUG	IL5 Antagonist or anti-IL5R-antibody or Omalizumab	mepolizumab, reslizumab, benralizumab and omalizumab in severe asthma

Timeline

• Start date: 2018-01-01
• Primary completion: 2020-10-31
• Completion: 2020-10-31
• First posted: 2019-11-08
• Last updated: 2023-12-04
• Results posted: 2023-12-04

Locations

1 site across 1 country: Finland

Regulatory

• FDA-regulated drug study